• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients.药物-药物相互作用和出院时的处方适宜性:COVID-19 患者的经验。
Drugs Aging. 2021 Apr;38(4):341-346. doi: 10.1007/s40266-021-00840-y. Epub 2021 Mar 1.
2
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.药物-药物相互作用和 COVID-19 患者的处方适宜性:来自意大利北部参考医院的回顾性分析。
Drugs Aging. 2020 Dec;37(12):925-933. doi: 10.1007/s40266-020-00812-8. Epub 2020 Nov 5.
3
Prevention of inappropriate prescribing in hospitalized older patients using a computerized prescription support system (INTERcheck(®)).使用计算机化处方支持系统(INTERcheck(®))预防住院老年患者的不适当处方。
Drugs Aging. 2013 Oct;30(10):821-8. doi: 10.1007/s40266-013-0109-5.
4
Potentially inappropriate medications involved in drug-drug interactions at hospital discharge in Croatia.克罗地亚医院出院时药物-药物相互作用涉及的潜在不适当药物。
Int J Clin Pharm. 2021 Jun;43(3):566-576. doi: 10.1007/s11096-020-01164-4. Epub 2020 Oct 1.
5
Potentially inappropriate prescribing in patients on admission and discharge from an older peoples' unit of an acute UK hospital.老年患者在英国急性医院老年人病房住院和出院时潜在不适当的处方。
Drugs Aging. 2013 Sep;30(9):729-37. doi: 10.1007/s40266-013-0097-5.
6
Medication-related factors associated with proton pump inhibitor prescription beyond official guidelines in older adults.与老年人超出官方指南的质子泵抑制剂处方相关的药物相关因素。
Eur Geriatr Med. 2020 Dec;11(6):1051-1061. doi: 10.1007/s41999-020-00380-5. Epub 2020 Aug 17.
7
Intervention to Improve Appropriate Prescribing and Reduce Polypharmacy in Elderly Patients Admitted to an Internal Medicine Unit.改善内科病房老年患者合理用药及减少多重用药的干预措施
PLoS One. 2016 Nov 30;11(11):e0166359. doi: 10.1371/journal.pone.0166359. eCollection 2016.
8
The impact of hospitalization on inappropriate prescribing and polypharmacy in older patients: A descriptive cross-sectional study.住院对老年患者不适当处方和多种药物治疗的影响:一项描述性横断面研究。
Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5812. doi: 10.1002/pds.5812.
9
Potentially Inappropriate Medication and Associated Factors Among Older Patients with Chronic Coronary Syndrome at Hospital Discharge in Beijing, China.中国北京慢性冠状动脉综合征老年患者出院时潜在不适当用药及相关因素。
Clin Interv Aging. 2021 Jun 9;16:1047-1056. doi: 10.2147/CIA.S305006. eCollection 2021.
10
Using two tools to identify Potentially Inappropriate Medications (PIM) in elderly patients in Southern Chile.使用两种工具识别智利南部老年患者中的潜在不适当用药(PIM)。
Arch Gerontol Geriatr. 2016 Nov-Dec;67:139-44. doi: 10.1016/j.archger.2016.08.001. Epub 2016 Aug 3.

引用本文的文献

1
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice.用于治疗新冠肺炎的心血管药物与奈玛特韦/利托那韦的相互作用:日常实践中的考量
Eur Cardiol. 2024 Aug 9;19:e15. doi: 10.15420/ecr.2024.04. eCollection 2024.
2
Potentially inappropriate medication as a predictor of poor prognosis of COVID-19 in older adults: a South Korean nationwide cohort study.潜在不适当用药作为老年人新冠病毒病预后不良的预测因素:一项韩国全国队列研究
BMJ Open. 2024 Jul 17;14(7):e073367. doi: 10.1136/bmjopen-2023-073367.
3
Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Pulmonary Aspergillosis: A 2-Year Study of a Multidisciplinary Outpatient Clinic.肺曲霉病患者多重用药及潜在药物相互作用的管理:一项对多学科门诊的两年研究
J Fungi (Basel). 2024 Jan 26;10(2):107. doi: 10.3390/jof10020107.
4
Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic.分枝杆菌感染患者的多重用药管理及潜在药物相互作用:一家多学科门诊诊所的1年经验
Antibiotics (Basel). 2023 Jul 10;12(7):1171. doi: 10.3390/antibiotics12071171.
5
Transformative Effect of COVID-19 Pandemic on Magnetic Resonance Imaging Services in One Tertiary Cardiovascular Center.新冠疫情对某三级心血管中心磁共振成像服务的变革性影响。
J Imaging. 2023 May 28;9(6):108. doi: 10.3390/jimaging9060108.
6
Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.评估富马酸恩曲他滨与细胞色素 P450 3A 底物在健康日本成年人中的药物相互作用潜力。
Clin Drug Investig. 2023 May;43(5):335-346. doi: 10.1007/s40261-023-01265-8. Epub 2023 May 12.
7
Clinical decision support systems to improve drug prescription and therapy optimisation in clinical practice: a scoping review.临床决策支持系统在改善临床实践中的药物处方和治疗优化中的应用:范围综述。
BMJ Health Care Inform. 2023 May;30(1). doi: 10.1136/bmjhci-2022-100683.
8
Evaluation of Drug Interactions in Hospitalized Patients with Respiratory Disorders in Greece.评估希腊呼吸疾病住院患者的药物相互作用。
Adv Respir Med. 2023 Feb 5;91(1):74-92. doi: 10.3390/arm91010008.
9
Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece.希腊新冠肺炎住院患者的药物相互作用
J Clin Med. 2022 Dec 2;11(23):7172. doi: 10.3390/jcm11237172.
10
Potentially inappropriate medications based on TIME criteria and risk of in-hospital mortality in COVID-19 patients.基于 TIME 标准的潜在不适当药物与 COVID-19 患者住院死亡率的关系。
Rev Assoc Med Bras (1992). 2022 Nov 28;68(12):1730-1736. doi: 10.1590/1806-9282.20220907. eCollection 2022.

本文引用的文献

1
Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study.低分子量肝素在新型冠状病毒肺炎住院患者中的作用:一项前瞻性观察研究
Open Forum Infect Dis. 2020 Nov 19;7(12):ofaa563. doi: 10.1093/ofid/ofaa563. eCollection 2020 Dec.
2
Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19.COVID-19 患者住院前使用质子泵抑制剂与临床结局的关系
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):137-141. doi: 10.1097/MEG.0000000000002013.
3
Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy.药物-药物相互作用和 COVID-19 患者的处方适宜性:来自意大利北部参考医院的回顾性分析。
Drugs Aging. 2020 Dec;37(12):925-933. doi: 10.1007/s40266-020-00812-8. Epub 2020 Nov 5.
4
Aging in COVID-19: Vulnerability, immunity and intervention.COVID-19 相关衰老问题:脆弱性、免疫与干预。
Ageing Res Rev. 2021 Jan;65:101205. doi: 10.1016/j.arr.2020.101205. Epub 2020 Oct 31.
5
The Double Burden of the COVID-19 Pandemic and Polypharmacy on Geriatric Population - Public Health Implications.新冠疫情与老年人群多重用药的双重负担——对公共卫生的影响
Ther Clin Risk Manag. 2020 Oct 20;16:1007-1022. doi: 10.2147/TCRM.S272908. eCollection 2020.
6
Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions.关于 COVID-19 和相关潜在药物相互作用导致病情恶化的合并症的荟萃分析。
Pharmacol Res. 2020 Nov;161:105250. doi: 10.1016/j.phrs.2020.105250. Epub 2020 Oct 13.
7
Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence.使用依诺肝素对抗新冠病毒感染并减少血栓栓塞性静脉并发症:当前证据综述
Front Pharmacol. 2020 Sep 16;11:579886. doi: 10.3389/fphar.2020.579886. eCollection 2020.
8
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia.新冠疫情时代心房颤动与癌症的综合管理:药物相互作用、血栓栓塞风险及心律失常
Curr Heart Fail Rep. 2020 Dec;17(6):365-383. doi: 10.1007/s11897-020-00485-9.
9
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.地塞米松对中重度 COVID-19 相关急性呼吸窘迫综合征患者存活天数和无呼吸机天数的影响:CoDEX 随机临床试验。
JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.
10
Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort.英国生物库队列中的多病共存、多种药物并用和 COVID-19 感染。
PLoS One. 2020 Aug 20;15(8):e0238091. doi: 10.1371/journal.pone.0238091. eCollection 2020.

药物-药物相互作用和出院时的处方适宜性:COVID-19 患者的经验。

Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients.

机构信息

Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy.

Unit of Clinical Pharmacology, ASST Fatebenefratelli-Sacco University Hospital, Milan, Italy.

出版信息

Drugs Aging. 2021 Apr;38(4):341-346. doi: 10.1007/s40266-021-00840-y. Epub 2021 Mar 1.

DOI:10.1007/s40266-021-00840-y
PMID:33646509
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7917961/
Abstract

BACKGROUND

Patients with coronavirus disease 2019 (COVID-19) are often elderly, with comorbidities, and receiving polypharmacy, all of which are known factors for potentially severe drug-drug interactions (DDIs) and the prescription of potentially inappropriate medications (PIMs).

OBJECTIVE

The aim of this study was to assess the risk of DDIs and PIMs in COVID-19 patients at hospital discharge.

METHOD

Patients with a proven diagnosis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who were hospitalized between 21 February and 30 April 2020, treated with at least two drugs, and with available information regarding pharmacological treatments upon admission and at discharge were considered. The appropriateness of drug prescriptions was assessed using INTERcheck.

RESULTS

A significant increase in the prescription of proton pump inhibitors and heparins was found when comparing admission with hospital discharge (from 24 to 33% [p < 0.05] and from 1 to 17% [p < 0.01], respectively). The increased prescription of heparins at discharge resulted in a highly significant increase in the potentially severe DDIs mediated by this class of drugs. 51% of COVID-19 patients aged > 65 years had at least one PIM upon admission, with an insignificant increment at discharge (58%).

CONCLUSION

An increased number of prescribed drugs was observed in COVID-19 patients discharged from our hospital. The addition of heparins is appropriate according to the current literature, while the use of proton pump inhibitors is more controversial. Particular attention should be paid to the risk of bleeding complications linked to heparin-based DDIs.

摘要

背景

患有 2019 年冠状病毒病(COVID-19)的患者通常为老年人,伴有合并症,并接受多种药物治疗,这些都是潜在严重药物相互作用(DDI)和潜在不适当药物(PIM)处方的已知因素。

目的

本研究旨在评估 COVID-19 患者出院时发生药物相互作用和潜在不适当药物的风险。

方法

考虑患有经证实的严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的患者,这些患者在 2020 年 2 月 21 日至 4 月 30 日之间住院,接受至少两种药物治疗,并且在入院和出院时可获得有关药物治疗的信息。使用 INTERcheck 评估药物处方的适宜性。

结果

与入院时相比,出院时质子泵抑制剂和肝素的处方显著增加(分别从 24%增加到 33%[p<0.05]和从 1%增加到 17%[p<0.01])。出院时肝素处方的增加导致该类药物介导的潜在严重药物相互作用显著增加。51%的>65 岁 COVID-19 患者入院时至少有一种 PIM,出院时无明显增加(58%)。

结论

从我们医院出院的 COVID-19 患者的处方药物数量有所增加。根据目前的文献,肝素的添加是合理的,而质子泵抑制剂的使用更具争议性。应特别注意与肝素类药物相互作用相关的出血并发症风险。